BioArctic AB

Name

BioArctic AB

Legal name

BioArctic AB

Website

https://bioarctic.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAAAAAH

Therapeutic Peptides & Protein/Peptide Biologics

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Neurodegenerative disease therapeutics
• Antibody drug development
• Blood-brain barrier delivery
• Biopharmaceutical licensing
• Alzheimer's therapeutics

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Leqembi Royalties: BioArctic receives tiered royalties on global sales of Leqembi from its long-standing partnership with Eisai (dating back to 2005). Royalty income has been growing significantly, reaching SEK 160.8 million in Q1 2026 (+68% YoY). Leqembi is approved in 53 countries with regulatory review ongoing in 6 more.
2. Milestone Payments: BioArctic receives milestone payments upon achievement of regulatory and sales milestones from partners. In Q1 2026, a EUR 20 million milestone was triggered when Leqembi global sales exceeded EUR 500 million. Additional milestones are tied to subcutaneous formulation approvals and sales targets.
3. Upfront and Milestone Payments from BrainTransporter Licensing: BioArctic receives upfront payments, milestone payments, and tiered royalties from licensing its BrainTransporter technology to pharmaceutical partners. Deal with Eli Lilly: $30M upfront + up to $770M milestones + mid-single-digit royalties. Deal with Novartis: $30M upfront + up to $772M milestones + mid-single-digit royalties. Deal with Bristol Myers Squibb: $100M upfront + up to $1.25B milestones + tiered low double-digit royalties.
4. Nordic Co-commercialization: BioArctic retains rights to co-commercialize Leqembi in the Nordic region alongside Eisai, generating revenue from direct product sales in Sweden, Norway, Finland, and Denmark.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

BioArctic AB is a Swedish research-based biopharma company developing antibody treatments for neurodegenerative diseases (primarily Alzheimer's and Parkinson's). Its flagship product is Leqembi (lecanemab), an amyloid-beta oligomer/protofibril antibody co-developed and globally commercialized by partner Eisai as the first proven disease-modifying treatment for early Alzheimer's disease. The company also licenses its proprietary BrainTransporter technology platform, a transferrin receptor-based system that ferries biologic drugs across the blood-brain barrier, to partners including Bristol Myers Squibb, Novartis, and Eli Lilly.

Product overview

BioArctic AB is a Swedish research-oriented biopharma company focused on innovative treatments for neurodegenerative diseases. The core product is Leqembi (lecanemab), the world's first proven disease-modifying drug for early Alzheimer's disease, developed with partner Eisai. Leqembi works by targeting harmful amyloid-beta oligomers and protofibrils. The company is expanding its formulation options with Leqembi Iqlik, a weekly subcutaneous autoinjector under regulatory review. BioArctic's proprietary BrainTransporter technology platform facilitates active transport of antibodies across the blood-brain barrier using the transferrin receptor, enhancing drug efficacy and enabling improved dosing. The pipeline includes exidavnemab for Parkinson's disease and Multiple System Atrophy (Phase 2a), plus licensed programs BAN1503 and BAN2803 for PyroGlutamate-amyloid-beta targeting (with Bristol Myers Squibb) and BAN2238 for alpha-synuclein in Parkinson's. The research portfolio spans Alzheimer's disease, Parkinson's disease, and ALS, with several projects utilizing the BrainTransporter platform either internally or through external partnerships (Eisai, Bristol Myers Squibb, Novartis, Eli Lilly).

Differentiator

Problem solved

Functional benefit

Brands

• Leqembi (lecanemab): World's first drug proven to slow the progression of Alzheimer's disease and reduce cognitive impairment in early Alzheimer's disease. Developed in partnership with Eisai.
• BrainTransporter
• Leqembi Iqlik

Products and services

• Leqembi (lecanemab) Leqembi (lecanemab) is a humanized monoclonal antibody that selectively binds to and clears the most toxic forms of amyloid-beta — soluble protofibrils and insoluble fibrils — for the treatment of early Alzheimer's disease (mild cognitive impairment and mild Alzheimer's dementia). It is the first disease-modifying treatment for early Alzheimer's disease, co-developed with Eisai and globally commercialized by Eisai (with BioArctic co-promoting in the Nordic region).
• BrainTransporter technology BrainTransporter is BioArctic's proprietary, patented drug-delivery technology that uses transferrin receptor-mediated active transport to ferry biologic drugs across the blood-brain barrier. It is licensed to pharma partners (Bristol Myers Squibb, Novartis, Eli Lilly) on a standalone basis to be incorporated into partners' antibody and biologic candidates, reducing the required drug dose, expanding brain exposure, and enabling less frequent dosing. It is sold via licensing, collaboration, and option-to-acquire agreements generating upfront payments, R&D funding, milestone payments, and tiered royalties.

Quantifiable outcome

• 31% reduction in clinical decline on CDR-SB cognitive scale at 18 months (Phase 3 Clarity AD trial, in ApoE ε4 non-carriers or heterozygotes)
• +6 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• Eli Lilly and CompanycoreStrategic or Co-development Partner · 22 June 2026Research and collaboration agreement to develop a potential neurodegeneration treatment combining BioArctic's BrainTransporter technology with an undisclosed Lilly drug candidate. BioArctic receives $30 million upfront, up to $770 million in milestone payments, and tiered mid-single-digit royalties on future global product sales. Lilly assumes full responsibility for global development and commercialization. This is BioArctic's fourth BrainTransporter collaboration.
• Novartis Pharma AGcoreStrategic or Co-development Partner · 26 August 2025Option, collaboration and license agreement using BrainTransporter technology for a neurodegeneration target. BioArctic received $30 million upfront. If Novartis exercises its option after evaluating initial research results, BioArctic is eligible for additional payments up to $772 million plus tiered mid-single-digit royalties. Novartis assumes responsibility for global development and commercialization if option is exercised. This is BioArctic's third BrainTransporter collaboration.
• Bristol Myers SquibbcoreStrategic or Co-development Partner · 19 December 2024Global exclusive license agreement for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803 (the latter includes BrainTransporter technology). BioArctic received $100 million upfront and is eligible for up to $1.25 billion in milestone payments plus tiered low double-digit royalties on global product sales. Bristol Myers Squibb assumes sole responsibility for global development and commercialization. BioArctic retains option to co-commercialize in the Nordic region.
• Eisai Co., Ltd.coreStrategic or Co-development Partner · 1 January 2005Long-standing collaboration dating back to 2005 for the development and commercialization of Leqembi (lecanemab). BioArctic invented Leqembi and co-developed it with Eisai. Eisai is responsible for global clinical development, regulatory interactions, and commercialization, while BioArctic receives milestone payments and tiered royalties on global sales. BioArctic retains co-commercialization rights in the Nordic region. Eisai has also entered a research evaluation agreement regarding BAN2802 using the BrainTransporter technology.
• Biogen Inc.coreStrategic or Co-development PartnerBiogen co-developed and co-commercializes Leqembi (lecanemab) with Eisai. BioArctic is the original inventor of Leqembi and works with Eisai as primary partner, with Biogen involved as co-commercialization partner with Eisai for the product.
• Uppsala UniversitycoreStrategic or Co-development PartnerBioArctic's Leqembi was originally developed based on research from Uppsala University led by Professor Lars Lannfelt on the Arctic mutation in Alzheimer's disease. The company maintains academic roots in Swedish research and co-founder Professor Lars Lannfelt continues to contribute to the company's scientific advisory.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Eli Lilly and Company: Major pharma developing Kisunla (donanemab) for early Alzheimer's disease and a BrainTransporter collaboration partner with BioArctic. Directly competes in the anti-amyloid Alzheimer's space and validates the BrainTransporter platform via the 2026 collaboration.
• Roche / Genentech: Major incumbent pharma with multiple Alzheimer's programs (gantenerumab history and ongoing CNS pipeline). Competes indirectly with Leqembi and is a potential future BrainTransporter or neurodegeneration partner for BioArctic.
• Novartis AG: Major pharma with active neurodegeneration R&D and a recent BrainTransporter option/license partner with BioArctic. Overlaps with BioArctic on CNS pipeline and validates the platform while posing broader competition in adjacent neurodegenerative indications.
• Bristol Myers Squibb: Major pharma that took an exclusive license to BioArctic's PyroGlu-Aβ program (BAN1503/BAN2803) for up to $1.35B. Both a key BioArctic partner and a broader neurodegenerative disease competitor via its large pharma pipeline.

Direct peers

• Eisai Co., Ltd. Long-standing BioArctic partner for Leqembi (lecanemab) since 2005 and global commercialization lead. Operates in the same neurodegenerative disease space as BioArctic and is effectively a co-developer of Leqembi, sharing the same disease-modifying Alzheimer's thesis.
• Biogen Inc. Co-commercialization partner with Eisai for Leqembi and historical developer of Aduhelm. Active in the same disease-modifying Alzheimer's space and shares commercial economics on BioArctic's flagship product.
• Denali Therapeutics: Clinical-stage biotech developing a transferrin receptor (TfR)-based blood-brain barrier delivery platform (ATV) plus neurodegenerative disease antibodies. Most direct technology peer to BioArctic's BrainTransporter franchise.
• Prothena Corporation: Clinical-stage biotech with a pipeline of antibody therapeutics for neurodegenerative diseases including Parkinson's (alpha-synuclein) and Alzheimer's. Comparable pipeline-stage biotech with similar CNS biologics strategy.

Emerging players

• AC Immune SA: Swiss clinical-stage biopharma developing anti-amyloid and tau-targeting therapeutics for Alzheimer's and other neurodegenerative diseases. Competes for partnership and capital in the same disease-modifying AD pipeline space.
• Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Competes for investor attention and partnership interest in the disease-modifying Alzheimer's space alongside BioArctic's Leqembi franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/bioarcticab
• Facebookfacebook.com/BioArctic
• LinkedInlinkedin.com/company/bioarcticab
• Instagraminstagram.com/bioarcticab

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioArctic AB